GMRS GMR Solutions Inc.
Executive Summary
GMR Solutions Inc. filed Amendment No. 3 to its S-1 registration statement for an IPO of 31,914,893 shares of Class A common stock at an expected price range of $22.00-$25.00 per share. The company is the largest U.S. provider of emergency medical services (EMS) with integrated air and ground operations, posting FY2025 revenue of $5.7B and net income of $206.2M. Proceeds will be used to redeem preferred stock and repay debt, while the controlling KKR stockholder will retain ~75.5% voting power post-offering.
Key Financial Metrics
Actionable Insight
Monitor final IPO pricing and demand; post-IPO focus on debt repayment progress and core revenue growth (excluding divestitures). The dual-class structure and KKR control limit minority shareholder influence. Q1 2026 trends suggest improving fundamentals.
Key Facts
- Offering 31,914,893 shares of Class A common stock at $22.00-$25.00 per share, with midpoint $23.50
- FY2025 revenue of $5,739.8M (down 4% YoY due to divestitures), net income $206.2M, Adjusted EBITDA $1,186.2M
- Q1 2026 preliminary revenue $1,415-$1,455M (up 3.5-6.4% YoY), net income $97-$102M (up 155-168% YoY)
- Post-IPO KKR Stockholder will control ~75.5% voting power; company will be a 'controlled company'
- Net proceeds ~$669.2M used for $299.3M preferred stock redemption and $770M debt repayment (combined with private placement)
- Substantial indebtedness of $5,045.9M as of Dec 31, 2025, excluding finance leases
- Largest U.S. EMS provider with ~5.5M annual patient encounters and operations in ~1,400 counties
Financial Impact
IPO proceeds of ~$669M plus $350M private placement used to reduce debt by ~$770M and redeem preferred stock
Risk Factors
- Massive debt load with $5.1B total debt; interest expense remains significant
- Controlling stockholder (KKR) interests may diverge from public shareholders
- Revenue decline in FY2025 due to divestitures; core growth depends on managed care contracting and volume
- Heavy reliance on government reimbursement (Medicare/Medicaid ~32% of revenue) and regulatory changes
- Significant dilution from outstanding warrants and equity awards
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001104659-26-058050 |
| Document: tm2518736d16_ex-filingfees.htm | 0001104659-26-058050 |
| Document: tm2518736d17_ex23-1.htm | 0001104659-26-058050 |
| Document: 0001104659-26-058050-index-headers.html | 0001104659-26-058050 |
| Document: 0001104659-26-058050-index.html | 0001104659-26-058050 |
| Document: 0001104659-26-058050.txt | 0001104659-26-058050 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
8d ago
|
8-K
| $10.61 $10.85 | ▲ +2.26% | ▲ +2.98% | $11.62 (+9.52%) |
|
May 18, 2026
22d ago
|
8-K
| $13.37 $12.07 | ▼ −9.72% | ▼ −9.07% | $11.62 (−13.09%) |
|
May 14, 2026
26d ago
|
424B4
| $13.85 $13.37 | ▼ −3.47% | ▼ −2.24% | $11.62 (−16.10%) |
|
May 13, 2026
27d ago
|
3
| $13.85 $13.85 | · 0.00% | ▼ −0.01% | $11.62 (−16.10%) |
|
May 13, 2026
27d ago
|
3
| $13.85 $13.85 | · 0.00% | ▼ −0.01% | $11.62 (−16.10%) |
|
May 13, 2026
27d ago
|
3
| $13.85 $13.85 | · 0.00% | ▼ −0.01% | $11.62 (−16.10%) |
|
May 13, 2026
27d ago
|
3
| $13.85 $13.85 | · 0.00% | ▼ −0.01% | $11.62 (−16.10%) |
|
May 13, 2026
27d ago
|
3
| $13.85 $13.85 | · 0.00% | ▼ −0.01% | $11.62 (−16.10%) |
|
May 13, 2026
27d ago
|
EFFECT
| $13.98 $13.85 | ▼ −0.93% | ▼ −1.71% | $11.62 (−16.88%) |
|
May 8, 2026
4w ago
|
S-1/A
| — | awaiting T+1 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access